Postchemotherapy Resection of Residual Mass in Nonseminomatous Germ Cell Tumor

被引:14
作者
Ghodoussipour, Saum [1 ]
Daneshmand, Siamak [1 ]
机构
[1] USC Inst Urol, Norris Comprehens Canc Ctr, 1441 Eastlake Ave,Suite 7416, Los Angeles, CA 90033 USA
关键词
Germ cell tumor; Testicular cancer; Nonseminomatous; Retroperitoneal lymph node dissection; LYMPH-NODE DISSECTION; GROWING TERATOMA SYNDROME; TESTICULAR CANCER; CLINICAL-IMPLICATIONS; SURGICAL-MANAGEMENT; OUTCOME ANALYSIS; TESTIS CANCER; RETROPERITONEAL; CHEMOTHERAPY; COMPLICATIONS;
D O I
10.1016/j.ucl.2019.04.004
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The introduction of cisplatin-based chemotherapy has revolutionized the care of patients with disseminated testicular germ cell tumors. Although a majority are cured with chemotherapy alone, surgical resection continues to play a role because one-third will have residual mass after chemotherapy. In this article, we review the current indications for postchemotherapy resection in nonseminomatous germ cell tumors, including masses greater than 1 cm, resection after salvage chemotherapy, with elevated markers, after late relapse, and for growing teratoma syndrome. We also highlight technical considerations of this often-challenging surgery, including the need for adjunctive procedures, extraretroperitoneal resections, and modern techniques to minimize morbidity.
引用
收藏
页码:389 / +
页数:11
相关论文
共 60 条
[1]   Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience [J].
Alanee, Shaheen R. ;
Carver, Brett S. ;
Feldman, Darren R. ;
Motzer, Robert J. ;
Bosl, George J. ;
Sheinfeld, Joel .
UROLOGY, 2016, 95 :128-131
[2]   Thoracoabdominal resection of retrocrural residual cancers [J].
Albers, P ;
Höltl, W ;
Heidenreich, A ;
Aharinejad, S .
AKTUELLE UROLOGIE, 2004, 35 (02) :141-150
[3]  
[Anonymous], UROL ONCOL
[4]   LATE RELAPSE OF TESTICULAR CANCER [J].
BANIEL, J ;
FOSTER, RS ;
GONIN, R ;
MESSEMER, JE ;
DONOHUE, JP ;
EINHORN, LH .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1170-1176
[5]   COMPLICATIONS OF PRIMARY RETROPERITONEAL LYMPH-NODE DISSECTION [J].
BANIEL, J ;
FOSTER, RS ;
ROWLAND, RG ;
BIHRLE, R ;
DONOHUE, JP .
JOURNAL OF UROLOGY, 1994, 152 (02) :424-427
[6]   Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection [J].
Beck, SDW ;
Foster, RS ;
Bihrle, R ;
Einhorn, LH ;
Donohue, JP .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6149-6156
[7]   Tumor marker levels in post-chemotherapy cystic masses: Clinical implications for patients with germ cell tumors [J].
Beck, SDW ;
Patel, MI ;
Sheinfeld, J .
JOURNAL OF UROLOGY, 2004, 171 (01) :168-171
[8]   Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma [J].
Carver, Brett S. ;
Shayegan, Bobby ;
Serio, Angel ;
Motzer, Robert J. ;
Bosl, George J. ;
Sheinfeld, Joel .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) :1033-1037
[9]  
Cary C, 2015, UROL ONCOL, V33, pe15, DOI DOI 10.1016/J.UR0L0NC.2014.07.013
[10]   Outcomes of Postchemotherapy Retroperitoneal Lymph Node Dissection Following High-Dose Chemotherapy With Stem Cell Transplantation [J].
Cary, Clint ;
Pedrosa, Jose A. ;
Jacob, Joseph ;
Beck, Stephen D. W. ;
Rice, Kevin R. ;
Einhorn, Lawrence H. ;
Foster, Richard S. .
CANCER, 2015, 121 (24) :4369-4375